Variables | n = 129 |  |
---|---|---|
Age | 54.0 ± 12.6 |  |
FIGO stage, n, (%) | ||
 I | 17 | (13.2%) |
 II | 76 | (58.9%) |
 III | 17 | (13.2%) |
 IV | 19 | (14.7%) |
Tumor size (cm) | 4.5 ± 1.5 |  |
SCC antigen (ng/mL) | 14.8 ± 28.1 |  |
Lymph node metastasis status, n, (%) | ||
 Pelvic lymph node | 61 | (47.3%) |
 Para-aortic lymph node | 18 | (14.0%) |
PET parameter | ||
 pSUVmax | 13.0 ± 6.9 |  |
 Nodal SUVmax | 2.3 ± 5.0 |  |
HPV infection, n (%) | 111 | (86.0%) |
Median follow-up (months) | 60 | Â |